Nuro Beauty technology co.,ltd

A new long-acting glucagon-like peptide-1 (GLP-1) analogue from Novo Nordisk for glycemic control in adults with type 2 diabetes who have received and/or sulfonylureas in addition to diet control and exercise. And reduce the risk of major cardiovascular adverse events (cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke) in adults with type 2 diabetes with cardiovascular disease.